Farshad Guirakhoo joins GeoVax as Senior Vice President, Research and Development

US biotechnology firm strengthens its scientific leadership team

GeoVax Labs, a biotechnology company developing human vaccines using its novel platform technology, says Farshad Guirakhoo has joined the firm as Senior Vice President, Research and Development.

Guirakhoo is a world-renowned virologist and brings more than 20 years of experience in the development of vaccines and monoclonal antibody products to GeoVax. He is a former Executive/Senior Director of Sanofi Pasteur.

In his new role, Guirakhoo will play a leading role in the expansion of GeoVax's product development pipeline, and will be integral to collaborating on the development and implementation of a growth strategy to build upon GeoVax's novel platform technology and expertise. He will also contribute to the company's ongoing efforts to develop and commercialise its HIV and Ebola vaccines.

'We are thrilled that Dr Guirakhoo will be joining us,' said Harriet Robinson, Chief Scientific Officer at GeoVax.

'There is substantial work to be done to successfully move our current vaccine programmes forward and to build upon our technology platform; we are fortunate to have a professional of Dr Guirakhoo's calibre adding his talents to the effort.'

Dr Guirakhoo has held senior management and scientific roles within the biotechnology industry with Vaxess Technologies, Hookipa Biotech, Sanofi Pasteur, Acambis and OraVax.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Zika outbreak gives rise to global fears

Zika may not be a new virus but its newly confirmed ability to cause foetal brain abnormalities makes the search for a treatment or a vaccine a high priority. Dr Sarah Houlton looks at the latest initiatives
Regulatory

GeoVax launches second clinical site to test HIV vaccine

University of Alabama to study effects of vaccine on patients with HIV
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now